herpes simplex virus thymidine kinase). This ADV/binary-tk induced equal or greater cell killing in a CEA-specific manner in vitro compared with the CEA-independent killing of a vector with a constitutive viral promoter driving HSV-tk (ADV/RSV-tk). To monitor adenovirus-mediated HSV-tk gene expression in vivo, we employed noninvasive nuclear imaging using a radioiodinated nucleoside analog ([ 1 31I]-FIAU) serving as a substrate
Introduction
As gene therapy is making progress with gene delivery systems, the importance of control of transgene expression becomes more and more evident. Suicide gene therapy under the control of strong constitutive viral promoters (CMV, cytomegalovirus immediate-early promoter; RSV, Rous sarcoma virus promoter) is an effective strategy in cancer treatment, but its use, especially for the treatment of liver metastases, is severely limited by organ toxicity. [1] [2] [3] [4] [5] Tumor-restricted gene expression through transcriptional targeting is an attractive approach to reduce toxicity and potentially increase efficacy of cancer gene therapy. It has been demonstrated that gene expression of highly efficient gene therapy vectors can be targeted to tumors using cell-type or tissue-type specific promoter elements. [6] [7] [8] [9] [10] [11] [12] Most of these tumor-specific promoters, however, are relatively weak resulting in insufficient transgene expression levels. Several studies have reported that a CEA promoter driving a prodrug gene could mediate selective gene expression in CEA-producing tumors. [13] [14] [15] [16] [17] [18] Brand et al also showed that a CEA promoter driving a suicide gene for the treatment of cancer for HSV-tk. [ 
31I]-FIAU-derived radioactivity accumulated after intratumoral injection of ADV/binary-tk only in the area of CEA-positive tumors with significantly less spread to the adjacent liver tissue than after administration of the universally expressed ADV/RSV-tk. Both viruses exhibited similar antitumor efficacy upon injection of liver metastases. Importantly, in vivo dose escalation studies demonstrated significantly reduced toxicity after intravenous administration of ADV/binary-tk versus ADV/RSV-tk. In summary, the increased therapeutic index of this novel, amplified CEAdriven suicide gene therapy vector is a proof of principle for the powerful enhancement of a weak tissue-specific promoter for effective tumor restricted gene expression.
Gene Therapy (2002) 9, 168-175. DOI: 10.1038/sj/gt/3301618 reduced systemic toxicity, and several attempts have been made to increase the promoter strength of the CEA promoter. 12, 18, 19 Adenoviruses transduce many cell types including postmitotic cells (eg hepatocytes) and tumor cells with high efficiency. These characteristics of adenoviral vectors explain the significant liver toxicity of adenovirus-mediated suicide gene therapy. [3] [4] [5] To overcome this major limitation we set out to generate an amplified CEA promoter for efficient transcriptional targeting of suicide gene expression. We constructed a binary promoter system by using the CEA promoter to drive a chimeric transcription factor consisting of the powerful herpes simplex virus VP16 transcriptional activation domain fused to the DNA-binding domain of the yeast protein GAL4, which then binds to the GAL4-binding sites upstream of a minimal promoter to activate suicide gene expression. 20 Our in vitro and in vivo data comparing adenovirus-mediated suicide gene therapy utilizing the binary promoter system versus a constitutively expressed viral promoter (RSV) demonstrate a strong, CEA-restricted antitumor activity of the binary system with significant reduction in liver toxicity.
Results

Construction of the binary promoter system
In order to create an amplified tumor-specific promoter for transcriptional targeting of a suicide gene we used the CEA promoter to drive an artificial transcription factor (GAL4/VP16 fusion protein), which consists of the DNAbinding domain of GAL4 and the strong herpes simplex virus VP16 transcriptional activation domain. Five copies of the consensus GAL4-binding site (G5B) were placed upstream of a TATA minimal promoter driving HSVtk. These two expression cassettes were inserted into the E1 region of a recombinant adenoviral vector to generate a single-vector system (pADV/binary-tk) (Figure 1 ).
Activity and specificity of the CEA binary system in vitro
We used transient transfections of CAT (chloramphenicol acetyl transferase) reporter gene constructs to test the activity of the CEA promoter, the binary CEA promoter construct (co-transfection of two plasmids: pCEA-GVP (GAL4/VP16) and pG5B(TATA)-CAT), and two constitutive viral promoters (pRSV-CAT, pCMV-CAT). CEA positive MOD cells were transfected with the different promoter constructs driving CAT. After standardization of transfection efficiency by ␤-gal co-transfection, the activity of pCEA-CAT was arbitrarily assigned the value of 1.0 and compared with the relative CAT activity of the other promoter constructs. The results showed that the CEA promoter was active in CEA-positive MOD cells with a dramatic amplification effect by the co-transfection of the two-plasmid binary system ( Figure 2 ). Transfection experiments after replacement of the CAT with HSVtk demonstrated equal cell killing activity of a single plasmid binary system versus the two-plasmid binary system and no cell killing with either component alone (pAD/CEA-GAL4/VP16 or pAD/G5B-tk) (data not shown). Recombinant adenoviruses were constructed expressing HSVtk under the control of the CEA binary promoter (ADV/binary-tk) or the RSV promoter (ADV/RSV-tk). Activity and specificity of these two viruses were tested by transduction of CEA-positive MOD cells and CEA-negative Hela cells at various multiplicities of infection (MOI). Cell killing was evaluated with and without GCV treatment (8 g/ml) after 5 days. As shown in Figure 3 , there was strong, CEA-dependent cell killing of the ADV/binary-tk of CEA positive MOD cells, but not of the CEA-negative Hela cells, whereas the ADV/RSV-tk was cytotoxic independent of the CEA status of the cells (ie killing in both cell lines). 
Assessment of HSV-tk expression
Efficacy and toxicity of ADV/binary-tk in vivo
In order to evaluate the efficacy of the ADV/binary-tk to induce tumor regression compared with ADV/RSV-tk and an empty control adenovirus (ADV/DL312), the three vectors were delivered intratumorally into CEApositive, hepatic breast cancer metastases (MOD). The results indicated that the ADV/binary-tk induced sig- nificant tumor regression when compared with controls (P Ͻ 0.0048, ANOVA) with equal efficacy as the ADV/RSV-tk ( Figure 6 ). While the CEA binary system proved to be as effective as a constitutively expressed viral promoter, it was important to verify that the CEAdependent tumor specificity would also translate into reduced liver toxicity, the major limiting factor of liverdirected suicide gene therapy. To address toxicity issues in the most stringent way, we injected escalating doses of ADV/binary-tk and ADV/RSV-tk systemically by tail vein followed by GCV treatment (intraperitoneal injection of 10 mg/kg twice daily for 5 days). Survival was evaluated and the acute liver toxicity was analyzed through serial measurements of serum ALT levels. Furthermore, liver inflammation in histological sections was semiquantitatively graded at the time of death or termination of the experiment (14 days). The survival at 14 days showed that animals injected with ADV/binary-tk tolerated much higher viral doses than the ADV/RSV-tk treated ones (2.5 × 10 9 p.f.u. versus 7.5 × 10 8 p.f.u.) with significantly less liver toxicity (ALT release and liver inflammation) (Figure 7) .
Discussion
Several studies from our group and others have demonstrated that suicide gene therapy is highly effective in local tumor control. 1, 21 Successful preclinical experiments with recombinant adenoviruses expressing suicide genes (eg HSVtk) in a variety of tumor models have already resulted in the initiation of clinical trials. 1, [22] [23] [24] [25] Recombinant adenoviruses, however, are highly efficient gene delivery vehicles with the ability to transduce postmitotic, nondividing cells (eg hepatocytes). Vector 'leakage' into the surrounding normal tissue, even after careful intratumoral injection, results in significant dose-limiting toxicity. 26 Thus, tumor-restricted transgene expression through transcriptional targeting is an attractive approach to increase the narrow therapeutic index of suicide gene therapy.
Tissue-specific or cell type-specific promoters, however, are usually too weak to achieve sufficient transgene expression. 27 The CEA promoter driving HSVtk has been used for CEA-restricted tumor killing, but its potency was inferior compared with constitutively active promoters. 12, [15] [16] [17] [18] 28 In this study, we describe a new strategy to enhance CEA-driven transgene expression while maintaining its tissue specificity. We constructed a binary system where the CEA promoter is driving a hybrid transcriptional activator (GAL4/VP16) which powerfully activates a minimal TATA promoter to induce transgene expression. In vitro transfection assays of CEA-positive cells with a two-plasmid CEA binary system driving a reporter gene (pCEA-GVP (GAL4/VP16) and pG5B (TATA)-CAT) confirmed the CEA-specific expression of this approach. Furthermore, the level of reporter gene expression by the CEA binary system was significantly higher than with the CEA promoter alone, and compared also favorably with other strong constitutively active viral promoters, such as RSV and CMV (Figure 2) .
In order to avoid the complications of a two-vector system, we then established the binary system expressing HSVtk in a single recombinant adenovirus. In vitro cell killing assays in CEA-positive and CEA-negative cells confirmed the specificity of this ADV/binary-tk system. Only CEA-expressing cells were killed by the ADV/binary-tk as opposed to the non-specific killing of an adenovirus containing a RSV promoter driving HSVtk. Moreover, cell killing efficacy of the binary system was comparable to that of the RSV promoter driven construct (Figure 3) . The specificity of the binary system in vivo was further confirmed by noninvasive nuclear imaging. Quantitative analysis of ADV/binary-tk gene transfer showed transgene expression only in the area of CEApositive tumors with significantly less spread to the adjacent liver tissue than after administration of the universally expressed ADV/RSV-tk (Figures 4 and 5) . Also, the ADV/binary-tk was equally as potent in tumor killing as the ADV/RSV-tk ( Figure 6 ).
It has previously been shown that the CEA promoter can confer tumor-specific suicide gene expression; however, high viral doses or an increase in GCV concentration accompanied by severe liver toxicity were necessary to achieve therapeutic effects. [3] [4] [5] 12 As toxicity is a major obstacle in suicide gene therapy, we wanted to confirm that the CEA-mediated specificity of the binary system would translate into an improved safety profile even after systemic administration of the virus. Intra- 
I]FIAU-derived radioactivity was observed in the ADV/binary-tk and ADV/RSV-tk transduced tumors. Relatively high levels of radioactivity were observed in peritumoral and remote liver tissue in animals transduced with the ADV/RSV-tk vector, whereas significantly lower levels of liver radioactivity were observed after transduction with the ADV/binary-tk vector. No hepatic accumulation of radioactivity was observed in the control vector ADV/DL312 (negative control, central area of each panel) injected tumors. Note the residual radioactivity at the injection site (orbital vein) and accumulation of [ 131 I]-iodide in the thyroid (indicating some breakdown of [
I]FIAU).
Figure 5 Quantification of HSVtk expression. Comparison of HSVtk expression in tumors and liver after treatment with ADV/RSV-tk (filled bars), ADV/binary-tk (open bars), and ADV/DL312 control vector (striped bars). The levels of radioactivity in CEA-positive MOD tumors, adjacent peritumoral tissue (adjacent liver), and peripheral liver tissue samples were assessed by gamma spectroscopy and expressed as percentage of injected dose per gram of tissue (%dose/g).
venous dose escalation studies demonstrated significantly reduced liver toxicity and mortality of the ADV/binary-tk treated animals versus the ADV/RSV-tk treated animals ( Figure 7 ). These data suggest that, at an effective viral dose with tolerable GCV concentrations, Gene Therapy 
u. of ADV/DL312 (control vector, striped bars), ADV/binary-tk (open bars) or ADV/RSV-tk (filled bars). GCV treatment was started on the following day and continued for 5 days. The mice were killed 30 days after tumor injection and the tumor size was measured by morphometric analysis (n = 8 per group). There was significant reduction in tumor size ADV/binary-tk group (P = 0.0048; ANOVA) when compared with the control group. No difference in tumor regression was observed between ADV/binary-tk and RSV-tk treatment (10 mice per group).
the ADV/binary-tk has the potential to induce tumor killing with reduced liver toxicity. In the present study, the ADV/binary system exhibited a lower toxicity profile (mortality, liver toxicity) than the ADV/RSV-tk. Although appearing small at first sight, a toxicity dose differential of 0.5 log in systemically delivered virus could result in a significant biological effect. Careful preclinical efficacy studies coupled with expanded toxicity studies including meticulous assessment of vector distribution and transgene expression (leakiness of the promoter) in the body and measurement of signs of a general inflammatory response to the vector (ie Th-1 cytokine levels, etc) after systemic administration of the construct will have to be undertaken before a possible clinical translation can be initiated.
u.) of ADV/RSV-tk (filled bars) or ADV/binary-tk (open bars) with GCV treatment. (a) Survival at 14 days. At the highest tolerated dose for ADV
More importantly, however, this study is a proof of principle for the powerful enhancement of the transcription signal of a weak tissue specific promoter for effective tumor-restricted gene expression. It is known that CEA is also expressed in the bile duct epithelial cells of the normal liver, which may explain the residual toxicity of the ADV/binary system utilizing the CEA promoter. 29 The inclusion of other promoters in the binary system with greater tumor specificity than CEA, which will result in an even better therapeutic index of a binary-tk therapy, is currently under investigation.
The nuclear imaging component of this study shows that selective HSVtk expression of the ADV/binary-tk vector can be monitored. The imaging paradigm is based on an established reporter system where HSVtk is also used as a reporter gene and radiolabeled FIAU is the reporter probe ([   131   I ]-FIAU). In summary, our results provide evidence that the ADV/binary-tk system is able to treat hepatic, CEA-positive breast cancer metastases with a high degree of efficiency and specificity. Considering the fact that our binary system significantly increased transgene expression while reducing toxicity, it could further be modified to include prodrugs with lower toxicity and higher affinity for HSVtk than GCV or in combination with more efficient HSVtk enzymes. 30 The use of a nonmammalian transcriptional activator ensures that no other endogenous genes are being activated. Moreover, this system is not limited to CEA-expressing tumors such as gastrointestinal tumors and a large percentage of breast and lung cancers, but it can be adapted for the treatment of other tumors in conjunction with a different cell-type or tissue-specific promoter. The binary system will undoubtedly profit from the intense investigation of many tissue-specific promoters and may ultimately emerge as a powerful tool for stringent gene expression in a wide variety of tumors. Our results also demonstrate that binary constructs can be used to image the expression of weak promoters in specific tissues, and can be used to monitor therapeutic gene expression in target tissue, as well as in sensitive organs to avoid potential toxicity.
Materials and methods
Cell lines
Hela cells, used as CEA-negative controls, were grown in RPMI 1640 with 10% fetal calf serum (FCS). 15, 31 293 Cells (adenoviral E1-transformed human embryonic kidney cells) were maintained in DMEM plus 10% FCS. 32 MOD cells, a CEA-positive murine breast adenocarinoma cell line derived from BALB/c mice, were cultured in DMEM/Ham-F12 with 5% FCS. 33 All culture media were purchased from GIBCO Invitrogen Corporation, (Carlsbad, CA, USA).
Construction of the binary system
We generated two plasmids: (1) pAD/CEA-GAL4/VP16 which contained the CEA promoter driving GAL4/VP16 fusion protein. We used the CEA promoter from Ϫ424 to Ϫ2 base pairs upstream from the translation initiation site as described by Schrewe et al. 34 The GAL4/VP16 consisted of the DNA-binding domain of GAL4 (amino acids 1-147) and the strong herpes simplex virus VP16 transcriptional activation domain (amino acids 411-455). 20, 35 (2) pAD/G5B-CAT with the reporter gene CAT (chloramphenicol acetyl transferase) driven by a TATA minimal promoter downstream of five copies of the consensus GAL4-binding sequence (G5B). To establish a single vector pAD/binary-tk, the CAT gene was replaced by HSVtk and the two expression cassettes were subcloned into the adenovirus shuttle vector pXCJL.1 vector. 36 Recombinant adenovirus, pAD/binary-tk or pAD/RSVtk was generated by contransfection of adenovirus shuttle vector (binary-tk or RSV-tk) with the adenovirus Gene Therapy backbone vector pJM17 into the 293 cells by calcium phosphate precipitation. 5 Single plaques were picked and purified by double cesium chloride gradient ultracentrifugation as described previously. 37 Virus particle titer was determined by optical absorbance at 260 nm, and infectious unit titer (p.f.u./ml) was quantitated by standard agarose overlay plaque assay on 293 cells.
Viral vectors
ADV/binary-tk: 1.5 × 10 11 p.f.u./ml; 6 × 10 12 vp (viral particles)/ml; ratio: 1:40. ADV/RSV-tk: 1.6 × 10 11 p.f.u./ml; 4.8 × 10 12 vp/ml; ratio: 1:30.
In vitro activity and specificity of the binary system (cell killing assay)
To compare CEA-dependent cell killing activity of ADV/binary-tk versus ADV/RSV-tk, CEA-positive MOD cells and CEA-negative Hela cells were transduced at different MOI. 6 × 104 cells per well were seeded in 24-well plates and transduced by adenovirus at 37°C for 1 h. The medium was then replaced and 12 h later GCV (8 g/ml) was added. After 4 days in culture, cells were trypsinized and stained with trypan blue for the quantification of viable cells.
Gamma camera imaging and quantitative autoradiography
The experimental protocol involving animals was approved by the Institutional Animal Care and Use Committee of the Memorial Sloan Kettering Cancer Center. In order to reduce variability in injection techniques, all the in vivo experiments (tumor implantation and virus injection) were performed by a single experienced surgeon. Liver tumors were produced in syngeneic BALB/c mice (Harlan Sprague-Dawley, Indianapolis, IN, USA). After laparotomy, the left lateral lobe of the liver was exposed, diligently mobilized, and placed/immobilized on a sterile gauze on the abdominal wall. The tip of a 30-gauge butterfly was then placed just beneath the liver surface. Without touching the needle, 1.5 × 10 6 MOD cells in 20 l HBSS were slowly injected subcapsularly at the tip of the left lateral liver lobe from an attached Hamilton syringe through the catheter over the period of 1 min as previously described. 38 Fourteen days after tumor implantation, a second laparotomy was performed and only mice bearing a 5 × 5 mm tumor were randomized to the experimental groups (smaller or larger tumors were not used). 3 × 10 8 p.f.u. of either ADV/RSV-tk, ADV/binary-tk, or DL312 vector were injected with a 30-gauge needle directly into the 5 × 5 mm hepatic tumors (in 50 l of 10 mm TRIS.HCl, pH 7.4/1 mm MgCl/10% (vol/vol) glycerol/polybrene, 20 g/ml) as a single dose slowly over 5 min in 10 l/min increment boluses. After the injection, the needle was left in the tumor for another 2 min to prevent reflux or leakage. Twenty-four hours after intratumoral virus injection, 300 Ci of no carrieradded [
131 I]-FIAU was administered i.v., and gamma camera imaging was performed 24 h later.
No carrier-added [ 131 I]FIAU was prepared by reacting 2'-fluoro-2'-deoxy-1-␤-d-arabinofuranosyl-uracil (FAU) with carrier-free 131 I using iodogen followed by isolation of the product by column chromatography as previously described. 39 One day before [ 131 I]FIAU administration, all animals received an i.p. injection of 0.9% NaI solution (1 ml) to block the thyroid uptake of radioactive iodide.
Gamma camera imaging was performed on a dualheaded ADAC Vertex gamma camera (ADAC, Milpitas, CA, USA) equipped with a high energy high resolution (HEHR) collimator. Planar images were obtained and reconstructed to a 512 × 512 matrix with 1.2 × 1.2 mm pixel size. After imaging, animals were killed and liver sections containing the tumors were prepared. Quantitative autoradiography was performed on these tissue sections as previously described. 39 To estimate organ dosimetry of radioiodinated [ 131 I]FIAU and to confirm the validity of the autoradiographic and gamma camera measurements of radioactivity, tissue samples were weighed and directly assayed for radioactivity using a Packard 5500 gamma spectrometer (Packard, Meriden, CT, USA).
In vivo anti-tumor efficacy and toxicity of ADV/binary-tk
Ten-to 12-week-old BALB/c mice were used in these experiments. The animal protocol was approved by the Institutional Animal Care and Use Committee of the Mount Sinai School of Medicine. To evaluate the antitumor effect of ADV/binary-tk compared with ADV/RSV-tk or control vector (ADV/DL312) on hepatic metastases of breast cancer, 1.5 × 10 6 MOD cells were inoculated into the liver as described above. After 14 days, the liver was surgically exposed, mice with 5 × 5 mm tumor sizes were selected, and randomly assigned into each group. The virus (2.5 × 10 8 p.f.u.) was injected into tumors in a volume of 50 l (see above). The next day, animals were treated with GCV (10 mg/kg twice daily) or PBS by intraperitoneal injection for 5 consecutive days. The mice were killed 30 days after tumor injection and the tumor regression was evaluated by quantitative histomorphometric analysis. To determine the toxicity of ADV/binary-tk versus ADV/RSV-tk escalating viral doses were injected into the tail vein of mice and treated with GCV or PBS as above. After 14 days, the survival rate was evaluated and the livers of animals died during the treatment period or those killed at the end of the experiment were evaluated histopathologically. Lobular inflammation was scored from mild (1+), moderate (2+), to severe (3+). Serum ALT levels were measured at 4, 8 and 14 days after virus injection.
